228 related articles for article (PubMed ID: 25957784)
1. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
Hoffmann K; Ganten T; Gotthardtp D; Radeleff B; Settmacher U; Kollmar O; Nadalin S; Karapanagiotou-Schenkel I; von Kalle C; Jäger D; Büchler MW; Schemmer P
BMC Cancer; 2015 May; 15():392. PubMed ID: 25957784
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
Wan X; Zhai X; Yan Z; Yang P; Li J; Wu D; Wang K; Xia Y; Shen F
Oncotarget; 2016 Dec; 7(50):83806-83816. PubMed ID: 27566566
[TBL] [Abstract][Full Text] [Related]
3. Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis.
Cai R; Song R; Pang P; Yan Y; Liao Y; Zhou C; Wang S; Zhou X; Wang H; Zhang H; Sun H; Ma H
BMC Cancer; 2017 Nov; 17(1):714. PubMed ID: 29110700
[TBL] [Abstract][Full Text] [Related]
4. Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.
Lee JE; Bae SH; Choi JY; Yoon SK; You YK; Lee MA
World J Gastroenterol; 2014 Jan; 20(1):235-41. PubMed ID: 24415877
[TBL] [Abstract][Full Text] [Related]
5. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
Cabrera R; Pannu DS; Caridi J; Firpi RJ; Soldevila-Pico C; Morelli G; Clark V; Suman A; George TJ; Nelson DR
Aliment Pharmacol Ther; 2011 Jul; 34(2):205-13. PubMed ID: 21605146
[TBL] [Abstract][Full Text] [Related]
6. Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes.
Ramanathan R; Sharma A; Lee DD; Behnke M; Bornstein K; Stravitz RT; Sydnor M; Fulcher A; Cotterell A; Posner MP; Fisher RA
Transplantation; 2014 Jul; 98(1):100-6. PubMed ID: 24503764
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance).
Hubbard JM; Mahoney MR; Loui WS; Roberts LR; Smyrk TC; Gatalica Z; Borad M; Kumar S; Alberts SR
Target Oncol; 2017 Apr; 12(2):201-209. PubMed ID: 27943153
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.
Dadu R; Waguespack SG; Sherman SI; Hu MI; Busaidy NL; Jimenez C; Habra MA; Ying AK; Bassett RL; Cabanillas ME
Oncologist; 2014 May; 19(5):477-82. PubMed ID: 24733667
[TBL] [Abstract][Full Text] [Related]
9. Assessment of disease control rate and safety of sorafenib in targeted therapy for advanced liver cancer.
Zeng D; Yu C; Chen S; Zou L; Chen J; Xu L
World J Surg Oncol; 2024 Apr; 22(1):93. PubMed ID: 38605359
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.
Yoo SY; Badrinath N; Woo HY; Heo J
Mediators Inflamm; 2017; 2017():5198798. PubMed ID: 28512387
[TBL] [Abstract][Full Text] [Related]
11. Which is more appropriate for the evaluation of HCC, RECIST or mRECIST criteria?
Xie Y; Lyu T; Wang J; Zou Y
Dig Liver Dis; 2024 Feb; 56(2):381. PubMed ID: 38071182
[No Abstract] [Full Text] [Related]
12. Imaging Delay Following Liver-Directed Therapy Increases Progression Risk in Early- to Intermediate-Stage Hepatocellular Carcinoma.
Stanneart J; Nunez KG; Sandow T; Gimenez J; Fort D; Hibino M; Cohen AJ; Thevenot PT
Cancers (Basel); 2024 Jan; 16(1):. PubMed ID: 38201639
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma.
Siegel AB; El-Khoueiry AB; Finn RS; Guthrie KA; Goyal A; Venook AP; Blanke CD; Verna EC; Dove L; Emond J; Kato T; Samstein B; Busuttil R; Remotti H; Coffey A; Brown RS
Liver Cancer; 2015 Mar; 4(2):115-25. PubMed ID: 26020033
[TBL] [Abstract][Full Text] [Related]
14. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy].
D'Angelo S; Germano D; Zolfino T; Sansonno D; Giannitrapani L; Benedetti A; Montesarchio V; Attili A; Buonadonna A; Barni S; Gasbarrini A; Burlone ME; Cillo U; Marenco S; Villa E; Giovanis P; Proserpio I; Saitta C; Magini G; Cengarle R; Fava G; Cuttone F; Calvani N; Angelico M; Di Costanzo F; Noto A; Poggi G; Marignani M; Cascinu S; Amoroso D; Palmieri V; Massa E; Crocè LS; Picardi A; Tumulo S; Erminero C; Lencioni R; Lorusso V
Recenti Prog Med; 2015 May; 106(5):217-26. PubMed ID: 25994538
[TBL] [Abstract][Full Text] [Related]
16. Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma.
Wang CH; Wey KC; Mo LR; Chang KK; Lin RC; Kuo JJ
Asian Pac J Cancer Prev; 2015; 16(9):3595-604. PubMed ID: 25987009
[TBL] [Abstract][Full Text] [Related]
17. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.
Li J; Qin S; Xu R; Yau TC; Ma B; Pan H; Xu J; Bai Y; Chi Y; Wang L; Yeh KH; Bi F; Cheng Y; Le AT; Lin JK; Liu T; Ma D; Kappeler C; Kalmus J; Kim TW;
Lancet Oncol; 2015 Jun; 16(6):619-29. PubMed ID: 25981818
[TBL] [Abstract][Full Text] [Related]
18. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M;
Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784
[TBL] [Abstract][Full Text] [Related]
19. The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.
Nakamura M; Yamada Y; Muro K; Takahashi K; Baba H; Sasaki Y; Komatsu Y; Satoh T; Mishima H; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Future Oncol; 2015; 11(10):1471-8. PubMed ID: 25963425
[TBL] [Abstract][Full Text] [Related]
20. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis.
Parikh ND; Waljee AK; Singal AG
Liver Transpl; 2015 Sep; 21(9):1142-52. PubMed ID: 25981135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
